VISCHER assisted Memo Therapeutics, a Basel/Zurich based spin-off company from the ETH Zurich, developing a disruptive platform technology for antibody discovery. This technology allows for the first time banking and mining the complete antibody repertoire of human and animal species by using nanoliter reactor technology thereby increasing throughput and performance of biological assays. The CHF 2.3 million financing round was led by Redalpine and other Swiss investors, including EVA Basel and Zürcher Kantonalbank. The team at VISCHER was led by Matthias Staehelin (Partner) with Moritz Jäggy (Associate), both Corporate.